
Arbutus Biopharma Corporation: shareholders and insiders
Price
$4.02
November 20, 2026Market cap $799M
What Ploutos Investor adds for Arbutus Biopharma
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- Profit over the last twelve months is well above what the business itself earned, because it includes large gains outside the business, such as on investments or from selling a business. The P/E is lower than the business alone would give.
Insiders and their shares
Purchases and sales by officers and directors, from their own Form 4 filings.
Reading the newest filings from the SEC. This part fills in on its own in a few seconds.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Roivant Sciences Ltd.Common Shares, without par valueShare of class19.5%
- Morgan Stanleywith 1 more personCommon SharesShare of class12.2%
- Two Seas Capital LPwith 2 more personsCommon Shares, without par valueShare of class9.40%
- Whitefort Capital Master Fund, LPwith 5 more personsCommon Shares, without par valueShare of class8.00%
- BlackRock, Inc.Share of class7.20%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Roivant Sciences Ltd.Common Shares, without par value | 19.5% | 29.88M | Oct 5, 20263 filings since Feb 18, 2025 | 13D/A | |
| Morgan Stanleywith 1 more personCommon Shares | 12.2% | 18.68M | Oct 7, 20264 filings since Feb 3, 2025 | 13G/A | |
| Two Seas Capital LPwith 2 more personsCommon Shares, without par value | 9.40% | 18.56M | May 15, 20263 filings since Aug 13, 2025 | 13G/A | |
| Whitefort Capital Master Fund, LPwith 5 more personsCommon Shares, without par value | 8.00% | 15.79M | Sep 4, 20264 filings since Feb 21, 2025 | 13G | |
| BlackRock, Inc. | 7.20% | 14.33M | Oct 27, 2026 | 13G/A |
What the holders on a 13D state as their purpose
From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.
Roivant Sciences Ltd.19.5%From the filing of Oct 5, 2026
Item 4 is hereby amended by adding the following to the end thereof: On August 24, 2026, the Issuer commenced a modified Dutch auction tender offer to purchase for cancellation up to US$230 million in value of its Common Shares at prices between US$5.00 and US$5.75 per Common Share (the "Offer"), which included the option for shareholders to make a proportionate tender. Roivant made a proportionate tender of its Common Shares in the Offer in order to maintain its proportionate ownership of the Common Shares following completion of the Offer. The Offer expired at 5:00 p.m., New York City time, on September 29, 2026. On October 1, 2026, the Issuer announced that it had taken up and accepted…
From the filing of Oct 5, 2026
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Millennium Mgmt (Englander)In the quarter
- Citadel Advisors (Griffin)In the quarter-80%
- D.E. ShawIn the quarter+205%
- AQR CapitalIn the quarter+83%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Millennium Mgmt (Englander) | 3.06M | $15M | 0.01% | |
| Citadel Advisors (Griffin) | 82.3K | -80% | $400.0K | 0.00% |
| D.E. Shaw | 1.16M | +205% | $5.6M | 0.00% |
| AQR Capital | 58.2K | +83% | $300.0K | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 12.4% of its shares outstanding were held short, -27.9% since the report before.
- Shares held short
- 24.57M
- 12.4%
- Since the report before34.05M on Sep 30, 2026
- -27.9%
- 4.3
- 5.66M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 52%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 6.31M
- Nov 15, 2023: Shares held short 6.73M
- Nov 30, 2023: Shares held short 6.18M
- Dec 15, 2023: Shares held short 6.19M
- Dec 29, 2023: Shares held short 6.22M
- Jan 12, 2024: Shares held short 6.43M
- Jan 31, 2024: Shares held short 6.12M
- Feb 15, 2024: Shares held short 3.69M
- Feb 29, 2024: Shares held short 4.07M
- Mar 15, 2024: Shares held short 4.13M
- Mar 28, 2024: Shares held short 4.55M
- Apr 15, 2024: Shares held short 5.17M
- Apr 30, 2024: Shares held short 5.81M
- May 15, 2024: Shares held short 5.34M
- May 31, 2024: Shares held short 5.03M
- Jun 14, 2024: Shares held short 5.37M
- Jun 28, 2024: Shares held short 6.01M
- Jul 15, 2024: Shares held short 7.02M
- Jul 31, 2024: Shares held short 6.80M
- Aug 15, 2024: Shares held short 6.64M
- Aug 30, 2024: Shares held short 6.06M
- Sep 13, 2024: Shares held short 6.56M
- Sep 30, 2024: Shares held short 7.36M
- Oct 15, 2024: Shares held short 7.79M
- Oct 31, 2024: Shares held short 6.54M
- Nov 15, 2024: Shares held short 6.06M
- Nov 29, 2024: Shares held short 5.82M
- Dec 13, 2024: Shares held short 5.97M
- Dec 31, 2024: Shares held short 5.95M
- Jan 15, 2025: Shares held short 6.64M
- Jan 31, 2025: Shares held short 6.72M
- Feb 14, 2025: Shares held short 7.21M
- Feb 28, 2025: Shares held short 8.41M
- Mar 14, 2025: Shares held short 9.57M
- Mar 31, 2025: Shares held short 9.85M
- Apr 15, 2025: Shares held short 11.05M
- Apr 30, 2025: Shares held short 11.19M
- May 15, 2025: Shares held short 11.50M
- May 30, 2025: Shares held short 12.75M
- Jun 13, 2025: Shares held short 12.84M
- Jun 30, 2025: Shares held short 13.77M
- Jul 15, 2025: Shares held short 13.64M
- Jul 31, 2025: Shares held short 12.98M
- Aug 15, 2025: Shares held short 12.51M
- Aug 29, 2025: Shares held short 10.55M
- Sep 15, 2025: Shares held short 11.16M
- Sep 30, 2025: Shares held short 10.14M
- Oct 15, 2025: Shares held short 9.86M
- Oct 31, 2025: Shares held short 9.92M
- Nov 14, 2025: Shares held short 10.56M
- Nov 28, 2025: Shares held short 11.21M
- Dec 15, 2025: Shares held short 10.74M
- Dec 31, 2025: Shares held short 12.54M
- Jan 15, 2026: Shares held short 13.07M
- Jan 30, 2026: Shares held short 13.56M
- Feb 13, 2026: Shares held short 15.00M
- Feb 27, 2026: Shares held short 14.76M
- Mar 13, 2026: Shares held short 16.41M
- Mar 31, 2026: Shares held short 16.17M
- Apr 15, 2026: Shares held short 17.80M
- Apr 30, 2026: Shares held short 17.74M
- May 15, 2026: Shares held short 16.44M
- May 29, 2026: Shares held short 16.98M
- Jun 15, 2026: Shares held short 17.52M
- Jun 30, 2026: Shares held short 17.11M
- Jul 15, 2026: Shares held short 19.65M
- Jul 31, 2026: Shares held short 20.24M
- Aug 14, 2026: Shares held short 18.46M
- Aug 31, 2026: Shares held short 18.92M
- Sep 15, 2026: Shares held short 18.48M
- Sep 30, 2026: Shares held short 34.05M
- Oct 15, 2026: Shares held short 24.57M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading55.9% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 55.9% of the shares in the reported trades were short sales, against 58.3% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 55.9%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 58.3%
- Change
- -2.4 pts
- Short sales a dayon average, of 1.12M shares
- 627.8K
- More than atof 3,666 US-listed companies, same days
- 70%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 72.9%
- Oct 15, 2026: Short sales 71.2%
- Oct 16, 2026: Short sales 74.7%
- Oct 19, 2026: Short sales 68.3%
- Oct 20, 2026: Short sales 51.4%
- Oct 21, 2026: Short sales 38.7%
- Oct 22, 2026: Short sales 39.5%
- Oct 23, 2026: Short sales 66.5%
- Oct 26, 2026: Short sales 75.7%
- Oct 27, 2026: Short sales 58.9%
- Oct 28, 2026: Short sales 49.2%
- Oct 29, 2026: Short sales 60.8%
- Oct 30, 2026: Short sales 56.5%
- Nov 2, 2026: Short sales 54.5%
- Nov 3, 2026: Short sales 60.6%
- Nov 4, 2026: Short sales 56.7%
- Nov 5, 2026: Short sales 44.1%
- Nov 6, 2026: Short sales 65.9%
- Nov 9, 2026: Short sales 46.2%
- Nov 10, 2026: Short sales 48.7%
- Nov 11, 2026: Short sales 45.5%
- Nov 12, 2026: Short sales 56.2%
- Nov 13, 2026: Short sales 62.7%
- Nov 16, 2026: Short sales 67.1%
- Nov 17, 2026: Short sales 58.6%
- Nov 18, 2026: Short sales 62.4%
- Nov 19, 2026: Short sales 63.5%
- Nov 20, 2026: Short sales 54.4%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IWCiShares Micro-Cap ETFWeight in the fund0.17%
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund0.16%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.11%
- IBBiShares Biotechnology ETFWeight in the fund0.06%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.05%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.03%
- IWMiShares Russell 2000 ETFWeight in the fund0.02%
- FESMFidelity Enhanced Small Cap Core ETFWeight in the fund0.02%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.02%
- VHTVanguard Health Care Index FundWeight in the fund0.01%
15 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 166
- Q4 2025: Managers 172
- Q1 2026: Managers 167
- Q2 2026: Managers 177
Institutional investors by quarter
The fund managers holding ABUS, quarter by quarter, from Q2 2015 to Q2 2025, 41 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 177 managers held 141M shares, worth $675M. During the quarter 34 opened a position, 24 closed one, 61 added and 40 trimmed.
The largest holders, Q2 2026
- Two Seas CapitalIn the quarter+2.9%
- Morgan StanleyIn the quarter-32%
- Whitefort Capital ManagementIn the quarter+5.8%
- BlackRockIn the quarter+6.2%
- State StreetIn the quarter+24%
- Rubric Capital ManagementIn the quarter+14%
- Vanguard Capital ManagementIn the quarter+4.8%
- BarclaysIn the quarter-2.5%
- Geode Capital ManagementIn the quarter+9.2%
- Goldman Sachs GroupIn the quarter+219%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Two Seas Capital | 19.10M | +2.9% | $92M |
| Morgan Stanley | 17.70M | -32% | $85M |
| Whitefort Capital Management | 15.79M | +5.8% | $76M |
| BlackRock | 13.77M | +6.2% | $66M |
| State Street | 7.87M | +24% | $38M |
| Rubric Capital Management | 7.53M | +14% | $36M |
| Vanguard Capital Management | 7.01M | +4.8% | $34M |
| Barclays | 4.21M | -2.5% | $20M |
| Geode Capital Management | 4.12M | +9.2% | $20M |
| Goldman Sachs Group | 3.51M | +219% | $17M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Arbutus Biopharma's filings show?
Who buys and sells is one part of Arbutus Biopharma's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Which well-known managers hold ABUS?
4 of the managers we track held the shares on Sep 30, 2026. The largest position was Millennium Mgmt (Englander)'s, worth $15M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.